Half-dose Kaletra tablet approved for paediatric use in the US

HIV Treatment Bulletin - Vol. 8, No. 11&12, November/December 2007

On 9 November 2007, the FDA approved a new half-strength lopinavir/r (Kaletra) tablet formulation, manufactured by Abbott Laboratories.

Each film-coated tablet of this new formulation contains 100 mg lopinavir and 25 mg ritonavir. The major changes to the label include clear instructions regarding the importance of accurate calculation of the dose of Kaletra to minimise the risk for medication errors and overdose or under dose, and the addition of tablet dosing to section 2.2 Pediatric Patients.

In a press release, Abbott announced that it would make the lower strength formulation available in resource-poor countries, where Kaletra is marketed under the brand name Aluvia.

This wider access programme is dependent on European approval. The timeline for the EMEA decision is unclear.

Sources: FDA list serve and Abbott press release (12 Nov 07)

2008-11-01
IB070811-11

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.